Sarepta Therapeutics CEO Severino files Form 3

Accepted by SEC EDGAR 07/29/2026 - 08:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. reported insider information for Michael Severino, who is identified as both a director and the company’s Chief Executive Officer. This Form 3 report lists no equity transactions or holdings, serving only to establish his status as a reporting insider.

Key Terms

insider filing, ten percent owner, reporting person

3 terms

insider filing regulatory

"INSIDER FILING DATA (Form 3) for Sarepta Therapeutics, Inc."

ten percent owner regulatory

"Field "is_ten_percent_owner" indicates ten percent owner status."

reporting person regulatory

"The "reportingPersons" section lists the reporting person’s name and roles."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Sarepta Therapeutics’ (SRPT) Form 3 reveal about Michael Severino?

The Form 3 identifies Michael Severino as both a director and Chief Executive Officer of Sarepta Therapeutics, Inc. It reports no stock transactions or holdings, functioning mainly to document his role as a reporting insider for the company.

Does the SRPT Form 3 report any stock purchases or sales by Michael Severino?

No. The Form 3 shows zero reported transactions, with buy, sell, acquire, dispose, and other transaction counts all at 0. It therefore does not disclose any purchases, sales, or other trades in Sarepta Therapeutics stock by Michael Severino in this filing.

Is Michael Severino listed as a ten percent owner in Sarepta Therapeutics’ (SRPT) Form 3?

No. The data field is_ten_percent_owner is set to 0, indicating he is not treated as a ten percent owner in this report. His insider status here is based on serving as Chief Executive Officer and director of Sarepta Therapeutics.

What officer title is disclosed for Michael Severino in the Sarepta Therapeutics (SRPT) Form 3?

The Form 3 lists Michael Severino’s officer title as Chief Executive Officer. It also marks him as a director, confirming he holds both executive and board roles at Sarepta Therapeutics, Inc. within this insider reporting context.

Does the Sarepta Therapeutics (SRPT) Form 3 show any derivative securities for Michael Severino?

No derivative positions are listed. The derivativeSummary is empty and the derivativeTransactionCount in the transaction summary is 0, indicating this report does not disclose any options, warrants, or other derivative securities for Michael Severino.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SEVERINO MICHAEL

(Last) (First) (Middle)

215 FIRST STREET

(Street)

MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/28/2026

3. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Michael Severino	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)